Patients and study design
NSCLC, cancer, cancer cachexia
ADVERSE EVENTS, CANCER, ADVERSE DRUG REACTIONS, NSCLC
Patients with stage III or IV NSCLC aged ≥20 years were randomized to receive 100 mg anamorelin or placebo once daily in the fasting state (1 h before breakfast) in a double‐blind manner for 12 weeks. Anamorelin was prescribed as a treatment to prevent the progression of cancer cachexia. The eligibility criteria and patient characteristics are summarized in the Supporting Information (Data We used the following endpoints: LBM (as determined by DEXA), body weight, and the QOL questionnaire for cancer patients treated with anticancer drugs (QOL‐ACD), assessed at baseline and at weeks 1 (except DEXA), 3, 6, 9, and 12. Either the General Electric Lunar system (General Electric, Wauwatosa, Wisconsin) or the Hologic system (Hologic, Bedford, Massachusetts) were used to measure LBM.QOL‐ACD comprised four domains (functional, physical, mental, and psychosocial) across 22 items, each of which is scored on a scale of 1–5, where 5 = best response and 1 = worst response.Safety was recorded throughout the study in terms of adverse events (AEs), adverse drug reactions (ADRs), laboratory tests, vital signs, and 12‐lead electrocardiography.